+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Fluzone High-Dose

  • PDF Icon


  • 12 Pages
  • January 2019
  • Region: Global
  • Citeline
  • ID: 4775268
Drug Overview
Fluzone HD (inactivated split virion; Sanofi Pasteur) is an inactivated influenza vaccine that contains antigens from two A strains and one B strain specified by the World Health Organization seasonally for influenza vaccination. The high-dose vaccine is four times more concentrated than the standard Fluzone vaccine, hence providing a higher antibody response. Fluzone HD was approved for use in persons aged =65 years in the US in December 2009.

Analyst Outlook
The superior efficacy of Fluzone High-Dose (HD) (inactivated split virion trivalent influenza vaccine [TIV]; Sanofi Pasteur) compared to standard-dose inactivated influenza vaccines (IIVs) has positioned it as one of the preferred options for the elderly in the US.

Table of Contents

Drug Overview
Product Profiles
Fluzone High-Dose : Seasonal influenza vaccines

Table 1: Fluzone High-Dose drug profile
Table 2: Approval history of Fluzone HD for seasonal influenza vaccination
Table 3: Late-phase trials of Fluzone HD for seasonal influenza vaccination
Table 4: Fluzone High-Dose for seasonal influenza – SWOT analysis